

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



Tong Ren Tang Technologies Co. Ltd.  
北京同仁堂科技發展股份有限公司

*( a joint stock limited company incorporated in the People's Republic of China with limited liability )*

(Stock Code: 1666)

## **ANNOUNCEMENT ON RESULTS OF SUBSIDIARY**

Reference is made to the announcement (the “**Announcement**”) dated 26 April 2018 published by Beijing Tong Ren Tang Chinese Medicine Company Limited (“**Tong Ren Tang Chinese Medicine**”), a subsidiary of Tong Ren Tang Technologies Co. Ltd. (the “**Company**”) whose shares are listed on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (stock code: 8138), in relation to the first quarterly results of Tong Ren Tang Chinese Medicine and its subsidiaries for the three months ended 31 March 2018.

This announcement is made pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following unaudited financial information of Tong Ren Tang Chinese Medicine and its subsidiaries for the three months ended 31 March 2018 as set out in the Announcement.

## CONDENSED CONSOLIDATED INCOME STATEMENT

	Unaudited	
	Three months ended	
	31 March	
	2018	2017
	HK\$'000	HK\$'000
Revenue	379,361	315,029
Cost of sales	(95,332)	(77,258)
<b>Gross profit</b>	<b>284,029</b>	237,771
Distribution and selling expenses	(62,606)	(47,616)
General and administrative expenses	(29,301)	(23,275)
Other gains	390	648
<b>Operating profit</b>	<b>192,512</b>	167,528
Finance income	3,719	2,808
Finance costs	(8)	(43)
Finance income, net	3,711	2,765
Share of losses of investments accounted for using the equity method	(443)	(52)
<b>Profit before income tax</b>	<b>195,780</b>	170,241
Income tax expense	(31,069)	(32,740)
<b>Profit for the period</b>	<b>164,711</b>	137,501
<b>Profit attributable to:</b>		
Owners of the Company	158,785	132,554
Non-controlling interests	5,926	4,947
	<b>164,711</b>	137,501
<b>Earnings per share attributable to owners of the Company (expressed in HK\$ per share)</b>		
Basic and diluted	<b>0.19</b>	0.16

## CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

	Unaudited	
	Three months ended	
	31 March	
	2018	2017
	HK\$'000	HK\$'000
<b>Profit for the period</b>	<b>164,711</b>	137,501
<b>Other comprehensive income:</b>		
<i>Item that may be reclassified to profit or loss</i>		
Change in value of available-for-sale financial asset	1,320	495
Currency translation differences	3,890	6,029
<b>Other comprehensive income for the period</b>	<b>5,210</b>	6,524
<b>Total comprehensive income for the period</b>	<b>169,921</b>	144,025
<b>Attributable to:</b>		
Owners of the Company	163,493	137,466
Non-controlling interests	6,428	6,559
<b>Total comprehensive income for the period</b>	<b>169,921</b>	144,025

## CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

	Unaudited								
	Attributable to owners of the Company								
	Share capital HK\$'000	Merger reserve HK\$'000	Other reserve HK\$'000	Statutory reserve HK\$'000	Exchange reserve HK\$'000	Retained earnings HK\$'000	Total HK\$'000	Non-controlling interests HK\$'000	Total equity HK\$'000
<b>At 1 January 2017</b>	938,789	(13,124)	355	5,295	(18,827)	1,210,053	2,122,541	104,696	2,227,237
<b>Comprehensive income</b>									
Profit for the period	-	-	-	-	-	132,554	132,554	4,947	137,501
<b>Other comprehensive income</b>									
Change in value of available-for-sale financial asset	-	-	495	-	-	-	495	-	495
Currency translation differences									
— Group	-	-	-	-	4,178	-	4,178	1,612	5,790
— Joint ventures	-	-	-	-	239	-	239	-	239
<b>Total comprehensive income</b>	-	-	495	-	4,417	132,554	137,466	6,559	144,025
<b>Transactions with owners in their capacity as owners</b>									
Transfer of retained earnings to statutory reserve	-	-	-	1,032	-	(1,032)	-	-	-
Capital injection into subsidiaries	-	-	-	-	-	-	-	3,758	3,758
<b>Total transactions with owners in their capacity as owners</b>	-	-	-	1,032	-	(1,032)	-	3,758	3,758
<b>At 31 March 2017</b>	938,789	(13,124)	850	6,327	(14,410)	1,341,575	2,260,007	115,013	2,375,020
<b>At 1 January 2018</b>	938,789	(13,124)	2,360	6,229	(6,512)	1,565,150	2,492,892	115,285	2,608,177
<b>Comprehensive income</b>									
Profit for the period	-	-	-	-	-	158,785	158,785	5,926	164,711
<b>Other comprehensive income</b>									
Change in value of available-for-sale financial asset	-	-	1,320	-	-	-	1,320	-	1,320
Currency translation differences									
— Group	-	-	-	-	2,849	-	2,849	502	3,351
— Joint ventures	-	-	-	-	539	-	539	-	539
<b>Total comprehensive income</b>	-	-	1,320	-	3,388	158,785	163,493	6,428	169,921
<b>Transactions with owners in their capacity as owners</b>									
Dividends to non-controlling interests	-	-	-	-	-	-	-	(561)	(561)
Capital injection into subsidiaries	-	-	-	-	-	-	-	1,890	1,890
<b>Total transactions with owners in their capacity as owners</b>	-	-	-	-	-	-	-	1,329	1,329
<b>At 31 March 2018</b>	938,789	(13,124)	3,680	6,229	(3,124)	1,723,935	2,656,385	123,042	2,779,427

By order of the Board  
**Tong Ren Tang Technologies Co. Ltd.**  
**Gao Zhen Kun**  
*Chairman of the Board*

Beijing, the PRC

26 April 2018

*As at the date of this announcement, the Board comprises Mr. Gao Zhen Kun, Mr. Gu Hai Ou, Mr. Rao Zu Hai, Mr. Li Bin, Mr. Wang Yu Wei and Ms. Fang Jia Zhi as executive Directors; Miss Tam Wai Chu, Maria, Mr. Ting Leung Huel, Stephen and Mr. Jin Shi Yuan as independent non-executive Directors.*